Home
/
Coherus Oncology, Inc.
/
Financials
/
Quarterly
Coherus Oncology, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Coherus Oncology, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2018
Sep 30, 2017
$1.56M
Nov 8, 2018
Q2
2018
Jun 30, 2017
$1.40M
Aug 8, 2018
Q3
2018
Jun 30, 2017
$1.40M
Nov 8, 2018
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$1.56M
Nov 6, 2017
Q2
2017
Jun 30, 2017
$1.40M
Aug 7, 2017
Q1
2017
Mar 31, 2017
$161.0K
May 8, 2017
Q3
2017
Sep 30, 2016
$162.84M
Nov 6, 2017
Q2
2017
Jun 30, 2016
$14.07M
Aug 7, 2017
Q1
2017
Mar 31, 2016
$12.36M
May 8, 2017
Q2
2016
Jun 30, 2015
$6.87M
Aug 9, 2016
Q1
2016
Mar 31, 2015
$5.81M
May 9, 2016
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($35.53M)
Nov 6, 2025
Q3
2025
Jun 30, 2025
$297.77M
Nov 6, 2025
Q2
2025
Jun 30, 2025
$297.77M
Aug 7, 2025
Q3
2025
Mar 31, 2025
($56.57M)
Nov 6, 2025
Q1
2025
Mar 31, 2025
($56.57M)
May 12, 2025
Q2
2025
Mar 31, 2025
($56.57M)
Aug 7, 2025
Q3
2025
Sep 30, 2024
($10.75M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($12.92M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($12.92M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
$102.88M
May 12, 2025
Q2
2025
Mar 31, 2024
$102.88M
Aug 7, 2025
Q3
2025
Mar 31, 2024
$102.88M
Nov 6, 2025
Q3
2024
Sep 30, 2023
($39.64M)
Nov 6, 2024
Q3
2024
Jun 30, 2023
($42.87M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($42.87M)
Aug 8, 2024
Q2
2024
Mar 31, 2023
($75.73M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($75.73M)
Nov 6, 2024
Q1
2024
Mar 31, 2023
($75.73M)
May 9, 2024
Q3
2023
Sep 30, 2022
($86.65M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($50.15M)
Aug 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($44.33M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($45.49M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($45.44M)
May 12, 2025
Q3
2025
Sep 30, 2024
($46.86M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($39.63M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($67.79M)
May 12, 2025
Q3
2024
Sep 30, 2023
($32.01M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($34.54M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($67.75M)
May 9, 2024
Q3
2023
Sep 30, 2022
($80.45M)
Nov 6, 2023
Q2
2023
Jun 30, 2022
($44.01M)
Aug 2, 2023
Q1
2023
Mar 31, 2022
($80.93M)
May 8, 2023
Q3
2022
Sep 30, 2021
($32.79M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($24.16M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($167.36M)
May 5, 2022
Q3
2021
Sep 30, 2020
$33.72M
Nov 8, 2021
Q2
2021
Jun 30, 2020
$65.31M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$40.87M
May 6, 2021
Q3
2020
Sep 30, 2019
$51.84M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$27.49M
Aug 6, 2020